ODT stock forecast
Our latest prediction for Odonate Therapeutics Inc's stock price was made on the Dec. 10, 2021 when the stock price was at 1.52$.
In the short term (2weeks), ODT's stock price should outperform the market by 4.02%. During that period the price should oscillate between -15.21% and +32.14%.
In the medium term (3months), ODT's stock price should outperform the market by 5.17%. During that period the price should oscillate between -45.21% and +75.01%.
Get email alertsCreate a solid portfolio with ODT
About Odonate Therapeutics Inc
Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Odonate’s initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Odonate’s goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -2.69$ per share.
The book value per share is 6.41$
Three months stock forecastDec. 10, 2021
Financials
Revenue USD | Gross Margin | Operating Income | Operating Margin | Net Income | Earnings Per Share | Dividends | Payout Ratio | Shares | Book Value Per Share | Operating Cash Flow | Cap Spending | Free Cash Flow |
---|---|---|---|---|---|---|---|---|---|---|---|---|
- | - | -92M | - | -102M | -2.69 | - | - | 38M | 6.41 | -95M | - | -95M |